Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.31 |
| ▸ | BRAF | P15056 | 1/20 | 0.30 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6792438 | 0.88 | PDPK1 (0.34) | PDPK1CDK2HCAR2 | |
| Bromide SCHEMBL1655616 | 0.87 | PDPK1 (0.34) | PDPK1CDK2HCAR2 | |
| SCHEMBL6793040 | 0.85 | HSD17B10 (0.34) | PDPK1CDK2 | |
| Hydrochloric Acid SCHEMBL6794509 | 0.85 | HSD17B10 (0.33) | PDPK1CDK2 | |
| Hydrochloric Acid SCHEMBL1656581 | 0.83 | HCAR2 (0.44) | PDPK1CDK2HCAR2BRAFMAPK3 | |
| SCHEMBL5482684 | 0.82 | PDPK1 (0.31) | PDPK1CDK2 | |
| SCHEMBL6792211 | 0.81 | HCAR2 (0.33) | PDPK1CDK2HCAR2 | |
| Trifluoroacetic Acid SCHEMBL1655959 | 0.80 | OPRD1 (0.34) | PDPK1CDK2 | |
| Trifluoroacetic Acid SCHEMBL6791711 | 0.80 | BRAF (0.38) | PDPK1CDK2BRAFMAPK3MAPK1 | |
| Trifluoroacetic Acid SCHEMBL6792875 | 0.80 | GABRA1 (0.34) | PDPK1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | PHARMACIA CORPORATION | 2004-07-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | MKNK2, MAPKAPK2, MAP3K2 | PDPK1 87/4885CDK2 29/4885HCAR2 1767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.